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Abstract
The serine protease CAP1/Prss8 is crucial for skin barrier function, lung alveolar fluid clearance and has been unveiled as
diagnostic marker for specific cancer types. Here, we show that a constitutive knockout of CAP1/Prss8 leads to embryonic
lethality. These embryos presented no specific defects, but it is during this period, and in particular at E13.5, that wildtype
placentas show an increased expression of CAP1/Prss8, thus suggesting a placental defect in the knockout situation. The
placentas of knockout embryos exhibited significantly reduced vascular development and incomplete cellular maturation. In
contrary, epiblast-specific deletion of CAP1/Prss8 allowed development until birth. These CAP1/Prss8-deficient newborns
presented abnormal epidermis, and died soon after birth due to impaired skin function. We thus conclude that a late
placental insufficiency might be the primary cause of embryonic lethality in CAP1/Prss8 knockouts. This study highlights a
novel and crucial role for CAP1/Prss8 in placental development and function.
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Introduction
Proteases or peptidases are enzymes able to catalyze the
hydrolysis of peptide bonds representing about 2% of all proteins
in human [1] or mouse [2]. Proteases are often involved in
signaling cascades, where a zymogen is cleaved and converted into
its active form, allowing amplification but also fine-tune regulation
of a signal. Moreover, endogenous protease inhibitors are present
within a cell, giving a high level of complexity for these proteins
in vivo [3]. They are involved in many processes, from the classical
digestive function, to cellular signaling and specific protein
cleavage. Caspases are important in apoptosis, matrix metallo-
proteinases (MMPs) are involved in tissue remodeling, thrombin
plays a key role during blood clotting, while deubiquitinating
enzymes (DUBs) are required for sub-cellular localization of
proteins. Serine proteases are implicated in cell growth, survival,
invasion, angiogenesis and inflammation and appear to be
involved in human disease, including cancer. Therefore, there is
a growing interest in developing therapies to control the activity
and expression of proteases [4], e.g., inhibitors of the angiotensin-
converting enzyme, in the treatment of hypertension.
Mouse channel activating protease 1, also termed CAP1/Prss8
for protease serine S1 family member 8, has been named for its
ability to increase ENaC-mediated sodium current in vitro [5,6]
and in vivo [7,8]. According to the peptidase classification [2], it
belongs to the subfamily A of the S1 chymotrypsin family as
trypsin and chymotrypsin. The S1 family is characterized by a
catalytic triad, histidin, aspartate and serine (HDS), that are
gathered to form the catalytic site by folding of the protein [9].
CAP1/Prss8 belongs to a subgroup of S1 serine proteases that are
anchored to plasma membranes via a glycosyl-phophatidylinositol
linkage (GPI-anchored) located at the lipid rafts that are important
for cell-cell communication [10–12]. Human CAP1/Prss8 has
been previously isolated from seminal fluids of prostate cancer
patients and named prostasin [13]. First described as a cancer
marker, it has later been linked to reduced tumor growth as seen
by reduced invasiveness of breast [14], gastric [15] and prostate
cancer [16,17].
Recent studies suggest that CAP1/Prss8 is linked to matriptase
(Prss14; MT-SP1) in a protease cascade [18–21]. Activation of
CAP1 by the protease hepsin [22] has also been described. Equally
associated with cancer [23], matriptase seems to act as a tumor
suppressor gene in vitro [24], an effect proposed to be mediated
through CAP1/Prss8 [25]. On the other hand, potential inhibitors
of CAP1/Prss8 are the hepatocyte growth factor activator
inhibitor-1 (HAI-1) [26], and nexin-1 (PN-1), which inhibits
CAP1/Prss8-induced sodium current in Xenopus oocytes [27].
Using mice carrying a conditional knockout allele of CAP1/
Prss8 [28], we have previously demonstrated that CAP1/Prss8 is
required for normal skin barrier function resulting in postnatal
death due to severe dehydration when CAP1/Prss8 is deleted in
skin [29]. In addition, increased expression of CAP1/Prss8 induces
severe skin defects [30]. Moreover, CAP1/Prss8 is involved in
water and salt balance in lung alveolar type II cells [7].
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Furthermore, we have recently described two spontaneous animal
models carrying mutations in the CAP1/Prss8 gene, presenting
skin defects and constitutively reduced basal activity of ENaC [8].
In the present study, we unveil a novel and important role of
CAP1/Prss8 during embryonic development. Our data clearly
illustrate that proper expression of CAP1/Prss8 in the placenta
triggers late placental labyrinth maturation, thereby maintaining
late gestation embryonic development and allowing the embryo to
develop to term.
Results
A Constitutive Knockout of CAP1/Prss8 Results in
Embryonic Lethality
Serine proteases are implicated in many physiological and
pathological processes. In order to uncover new roles of the
membrane-bound serine protease CAP1/Prss8, we generated
constitutive knockouts of CAP1/Prss8 (D/D) by intercrossing
heterozygous mutant mice (D/+). CAP1/Prss8 knockout mice
were missing at weaning (Fig. 1A), and at birth (data not shown),
suggesting embryonic lethality. To identify the cause we dissected
embryos from E8.5 to E16.5 and determined the representation of
each genotype (Fig.1B). CAP1/Prss8 knockout mice were found
underrepresented, and none of the knockout embryos was found
alive from E14.5 onwards as determined by lack of heart beating
and visible pulsatile blood vessels. Examination of the knockout
embryos did not reveal any obvious developmental defects, like
neural tube closure, or heart malformations (Fig. 1C). Most often,
only the placenta and/or the degraded dead CAP1/Prss8
knoxkout embryo were found (Fig. 1C).
Late Differentiation Defect is Detected in CAP1/Prss8
Knockout Placentas
While wildtypes and heterozygotes showed an organized
arborization of the vessels starting from the umbilical cord,
placentas of knockout embryos exhibited only a couple of large
vessels and marginal ones (Fig. 2A). Histopathological analysis of
E12.5 to E14.5 embryos revealed that knockout placentas are less
organized with less marked placental cotyledons, and fewer blood
vessels at E14.5. At E12.5 and E14.5, the labyrinth size did not
differ amongst the experimental and control groups (E12.5; wt:
8756120 pixel; het: 8906267 pixel; ko: 7326149 pixel versus
E14.5; wt: 9456259 pixel; het: 1346665 and ko: 8876275 pixel)
(see also Fig. 2B). At the cellular level, a regular transition of the
placenta histology can be observed in wildtypes. At E12.5, the
placenta is mainly composed of cuboidal cytotrophoblasts that are
fusing to form a syncytium from E10.5 to E16.5. This results in a
thinner separation between maternal blood (small anucleate
erythrocytes) and the fetal blood (large nucleated erythrocytes).
In addition, the surface of exchange progressively increases. This
process is observed in heterozygotes as well. In contrast, knockout
placentas showed a majority of cuboidal cytotrophoblasts at E12.5
and this was maintained at all later time points, indicating
incapability to form a proper syncytium (Fig. 2C).
All together, these data highly suggest an altered development of
the placenta of knockout embryos from E12.5 onwards.
Increased Transient CAP1/Prss8 Expression is Required
for Normal Placenta Maturation
To evaluate the importance of CAP1/Prss8 in the placenta, we
followed its expression level by quantitative RT-PCR. In wildtype,
CAP1/Prss8 mRNA transcript expression in the placenta increas-
es from E11.5 onwards, reaching a peak around E13.5 before
declining to basal levels (Fig. 3A). No CAP1/Prss8 expression was
detected in placenta from knockout embryos, while heterozygotes
showed an intermediate expression level (Fig. 3A). In the embryo
itself, the expression level of Prss8 was increasing 2-fold between
E12.5 and 14.5 but overall remained 10- to 100-fold lower than in
the placenta. At time points considered in this study, no transient
peak of Prss8 expression was detected in the knockout embryo
(data not shown; see also Fig. 3A). Interestingly, the peak of
CAP1/Prss8 expression in wildtype placentas overlapped with the
Figure 1. Constitutive CAP1/Prss8 inactivation results in embryonic lethality. Distribution of genotypes following heterozygote breeding.
Number of wildtype (WT, black) CAP1/Prss8 heterozygous mutant (Het, grey) and knockout (KO, white) mice at weaning (A). Survival curves in
percentage of wildtype (black diamonds), heterozygous mutant (grey spares) and knockout (black diamonds) littermate embryos between E8.5 and
E16.5. Note, that no knockout embryo survived beyond E14.5 (B). (C) Representative pictures of gross morphology of embryos at different
developmental stages from wildtype (WT), heterozygous mutant (Het) and homozygous mutant (KO) mice. The black cross indicates dead/partially
degraded embryos; ***P,0.001.
doi:10.1371/journal.pone.0055796.g001
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reduced survival and the abnormal placental development in
knockouts (Fig. 3B).
To study further the consequences of CAP1/Prss8-deficiency,
we analyzed the mRNA transcript expression of the markers pRb,
Gcm1, EOMES and PAR2. pRb, EOMES and Gcm1 are
transcription factors involved in placental differentiation and/or
development. Absence of retinoblastoma protein (pRb) leads to a
placental defect and embryonic death at E14.5 [29]. In our study,
pRb expression in wildtype placentas increased from E11.5 to
E14.5, and this was not affected by the absence of CAP1/Prss8
(Fig. 3C). The T-box transcription factor Eomesodermin (Eomes)
is involved in the formation of the extra-embryonic trophoblast
lineage [30]. Eomes is necessary for gastrulation and early events
of placenta formation. We found that Eomes expression in the
placenta decreased with time showing no difference between
wildtype and knockout (Fig. 3C). The Protease-Activated
Receptor-2, PAR2, is a G-coupled receptor found to be activated
by CAP1/Prss8 in mouse embryo and in the skin [30]. Our results
show that PAR2 is equally expressed in the placenta of both
wildtype and knockout embryos (Fig. 3C). The knockout of the
glial cell missing 1 (Gcm1) transcription factor leads to a failure of
branchomorphogenesis and labyrinth formation from E8.5
onwards. Interestingly, Gcm1 promotes the fusion of the
cytotrophoblast and syncytiotrophoblast [31]. In wildtype placen-
ta, Gcm1 mRNA expression increased till E13.5, and did not
significantly differ from the knockout placenta (Fig. 3C).
Specific Inactivation of CAP1/Prss8 in the Epiblast is
Compatible with Embryonic Development Until Birth
To distinguish whether the observed embryonic lethality is
primarily caused by embryonic death or placental failure, we
targeted CAP1/Prss8 deletion specifically in the epiblast using
Sox2::Cre transgenic mice, aiming to delete CAP1/Prss8 in the
embryo proper, but not in the placenta. Expression from the
Sox2::Cre transgene induces recombination in the epiblast from
E6.5 onwards but not in extra-embryonic cell types. Following
CAP1/Prss8D/+; Sox2::CreTg/+ x CAP1/Prss8lox/lox breeding, we
genotyped embryos and found both knockout (CAP1/Prss8lox/
D;Sox2::CreTg/+), and control animals at E14.5 (CAP1/Prss8lox/D,
CAP1/Prss8lox/+ and CAP1/Prss8lox/+;Sox2::CreTg/+, Fig. 4A).
CAP1/Prss8 mRNA transcript expression was detected by
quantitative RT-PCR in the placenta of the conditional knockouts
while it was completely absent in the embryo itself (Fig. 4B). The
placentas of the heterozygous mutant (CAP1/Prss8lox/+; Sox2::-
CreTg/+) embryos retained intermediate levels of CAP1/Prss8
expression compared to knockout (CAP1/Prss8lox/+ and CAP1/
Prss8lox/D;Sox2::CreTg/+), as expected from the genotype
(Fig. 4B). Histologically, the placentas of all genotypes presented
a comparable and normal development at E14.5 with syncytio-
trophoblasts composing the majority of a matured labyrinth
(Fig. 4C). Moreover, the CAP1/Prss8lox/D; Sox2::Cre+ knockout
embryos were morphologically indistinguishable from the controls
(data not shown).
To assess the consequences of the lack of CAP1/Prss8 in the
embryos during the perinatal period, two litters were monitored
until birth. Conditional knockouts were born according to the
expected Mendelian distribution (Fig. 5A). Histological observa-
tion of the skin of the CAP1/Prss8lox/D;Sox2::CreTg/+ pups right
after birth showed hyperkeratosis (Fig. 5C). This is a characteristic
phenotype of skin-specific CAP1/Prss8 knockout animals as has
been previously described and leads to early postnatal death due to
severe dehydration [29]. Four more litters from the same breeding
(CAP1/Prss8D/+; Sox2::CreTg/+ x CAP1/Prss8lox/lox) were kept
until weaning, and no knockout (CAP1/Prss8lox/D; Sox2:: CreTg/+)
mice could be detected at that time point (Fig. 5B).
We concluded that the lack of CAP1/Prss8 in the embryo is
compatible with normal placenta function and embryo develop-
ment demonstrating that the embryonic death of constitutive
CAP1/Prss8 knockout animals is primarily caused by placenta
failure.
Discussion
Placenta and embryo are highly dependent on each other and
form a tightly regulated system with a placenta progressively
adapting to the increasing requirements of the embryo. To
determine the consequences of CAP1/Prss8 deficiency during
embryonic development, we analyzed in detail a complete CAP1/
Prss8 knockout mouse model, and found that the absence of the
protein leads to embryonic lethality. The present study shows a
novel important role of the membrane-bound serine protease
CAP1/Prss8 in placental development during late gestation.
Looking at different time points during embryonic development,
we found that 50% of the knockout embryos were dead at day
E12.5 or E13.5, and 100% from day E14.5 onwards (Fig. 1). We
therefore concluded that CAP1/Prss8 deletion resulted in
Figure 2. CAP1/Prss8 knockout placentas present a late differentiation defect. Representative pictures of placenta. (A) Placental discs at
E12.5 and E14.5. H&E stainings of sagittal sections of placentas at E12.5 and E14.5 from wildtype (WT), heterozygous (Het) and knockout (KO) embryos
at (B) low (x50) and at (C) high magnification (x400). From day E12.5 onwards, maturation from cytotrophoblasts to syncytiotrophoblasts is observed
in wildtype and heterozygous mutant but not in knockout. The dashed line indicates the limit between the labyrinth and the decidua in B, and
surrounds the cytotrophoblasts in C.
doi:10.1371/journal.pone.0055796.g002
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increased embryonic lethality. No obvious developmental delay
and/or defect was observed in E12.5 embryos. Cell proliferation
(Ki67) and TUNEL staining, and vascularization of the placenta,
as visualized by the staining for the endothelial cell marker CD31,
was not different from the wildtype (data not shown), thus rather
suggesting a functional defect. From that time point onwards, we
found the knockout embryos at varying developmental stages, and
they often presented signs of advanced post-mortem degradation
as illustrated in Fig. 1C, and thus were not informative for the
cause of lethality (Fig.1).
The placenta from CAP1/Prss8 knockout embryos appears pale
and lacks the arborescence of vessels as observed in wildtype
embryos at E14.5 (Fig. 2). From day E12.5 to E16.5, wildtype
placentas undergo major modifications. The labyrinth of the
placenta allows the maternal and embryonic gas and nutrient
exchange [31]. Trophoblastic cells develop from cuboidal and
proliferative cytotrophoblasts to thin and highly differentiated
syncytiotrophoblast cells, thereby increasing the exchange surface
and capacity (Fig. 2). The placenta from CAP1/Prss8 knockouts
apparently failed to undergo this maturation step, and histological
observation indicated that cytotrophoblasts are still mainly present
and are not replaced by syncytiotrophoblasts, preventing the
development of blood vessels. The development of knockout
placentas appeared to be modified from E12.5 onwards. We
cannot exclude, however, that functional impairment may precede
histopathological changes in the knockout placentas.
To evaluate the importance of CAP1/Prss8 expression in the
placenta, we measured mRNA levels by quantitative RT-PCR.
We first noticed that placental CAP1/Prss8 expression in wild-
types peaks at E13.5, at a time point where only less than 50% of
knockout embryos survived (Fig. 3). It is worth noting that the
maternal placenta shows only neglectable expression of CAP1/
Prss8 (data not shown). The peak of CAP1/Prss8 expression (at
E13.5) parallels the Gcm1 expression peak in wildtype. Gcm1 is a
transcription factor that promotes the late phase of differentiation
of the trophoblast lineage [32] by regulating the activity of the
Figure 3. mRNA transcription profile of placental-specific markers. Placental expression of CAP1/Prss8 (Prss8) (A) of wildtype (WT, black
diamond), heterozygous (Het, grey box), and knockout (KO, open triangle) embryos. **Shows the statistical difference between wildtype and
heterozygous level. (B) Overlay of the CAP1/Prss8 peak of expression in wildtype placenta (solid line) and the survival curve of knockout embryos
(dotted line). (C) Relative mRNA expression levels of Par2, pRb, Eomes and Gcm1 were determined in placenta from wildtype, heterozygous mutant
and knockout embyros from E11.5 to E14.5, each time point representing the average value measured from at least 3 animals.
doi:10.1371/journal.pone.0055796.g003
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placental-specific enhancer of the aromatase gene (CYP19) [33].
Interestingly, it was not significantly different between the
experimental and control group (Fig. 3C), and might thus not
represent the primary cause of lethality. The expression level of
Eomes that is involved in the development of the trophoblast
lineage did not differ in the knockout and control placenta
(Fig. 3C). Moreover, the mRNA transcript expression of the
protease-activated receptor PAR2, recently identified as down-
Figure 4. CAP1/Prss8 knockout embryos present normal placentas. Epiblast-specific CAP1/Prss8 knockout (Lox/D cre+) pups were obtained
by mating CAP1/Prss8D/+;Sox2::CreTg/+ to CAP1/Prss8lox/lox mice. (A) Genotype distribution of embryos recovered at E14.5 and relative quantification of
CAP1/Prss8 mRNA expression levels in placentas and embryos (B). CAP1/Prss8lox/D;Sox2::CreTg/+, embryo-specific knockout (Lox/D Cre+), white bar;
CAP1/Prss8lox/D (Lox/D Cre-) and CAP1/Prss8lox/+;Sox2::CreTg/+, heterozygous mutant (Lox/+ Cre+), grey bar; CAP1/Prss8lox/+ wildtype (Lox/+ Cre-); black
bar. Note that the CAP1/Prss8 mRNA expression in the knockout (Lox/D Cre+) embryos is abolished while the corresponding control (Lox/+ Cre+)
placentas show heterozygous expression levels. (C) H&E staining of sagittal placenta sections at E14.5 from controls (CAP1/Prss8lox/+; Lox/+ cre-),
heterozygotes (CAP1/Prss8lox/D; Lox/D) and embryo-specific knockouts (CAP1/Prss8 lox/D;Sox2::CreTg/+; Lox/D cre+).
doi:10.1371/journal.pone.0055796.g004
Figure 5. CAP1/Prss8 knockout embryos are born and exhibit an abnormal epidermis. Genotype distribution of pups at birth and at
weaning (CAP1/Prss8D/+;Sox2::CreTg/+ x CAP1/Prss8lox/lox). Two litters were taken right after birth (n = 21 pups, A) or following weaning (3 week-old;
n = 26 pups, B) and genotyped. (C) H&E staining of sagittal backskin sections of one-day-old pups from controls (CAP1/Prss8lox/+; Lox/+ cre-),
heterozygous (CAP1/Prss8lox/D; Lox/D cre-) and embryo-specific knockouts (CAP1/Prss8lox/D;Sox2::CreTg/+; Lox/D cre+). The latter displayed a compact
stratum corneum (hyperkeratosis) indicative of a skin barrier defect. Four additional litters were genotyped at weaning; magnification x200.
doi:10.1371/journal.pone.0055796.g005
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stream target of CAP1/Prss8 [30], was not altered at that
developmental stage. Hepatocyte growth factor activator inhibitor
(HAI-1) can form inhibitor complexes with several trypsin-like
serine proteases and is required for mouse placental development
and embryo survival [34]. HAI-1 is coexpressed with matriptase
and CAP1/Prss8 in chorionic trophoblasts, and ablation of HAI-1
led to a complete loss of undifferentiated chorionic trophoblasts
after E9.5 [34]. In contrary, genetic ablation of matriptase activity
in HAI-1-deficient embryos restored the integrity of chorionic
trophoblasts and development to term [34]. Till E12.5, we did not
detect any alterations in trophoblast development in our CAP1/
Prss8-deficient embryos, suggesting that their functions may
overlap, but they do not seem to be part of the same serine
protease cascade.
A known target of CAP1/Prss8 is the epithelial sodium channel
ENaC. Whereas a recent study suggested a role of ENaC in
decidual cells for embryo implantation, mice lacking ENaC
activity seem not affected during embryonic development and
are born according to the expected Mendelian distribution
[35,36]. Thus, we consider a major implication of ENaC in
placental development as rather unlikely.
The close relationship between the embryo and placenta still
leaves the question of the primary cause, leading to the death of
both the placenta and the embryo. We here hypothesize that the
placenta fails to develop which results in embryonic death, but on
the other hand, when the embryo dies, the placental development
may stop likewise. To test this hypothesis, we deleted CAP1/Prss8
exclusively in the epiblast, while placental CAP1/Prss8 expression
was maintained. At birth, all expected genotypes were present
following the Mendelian distribution (Fig. 5A), while no
constitutive knockout developed to term (Fig. 5). mRNA analyses
showed that we indeed successfully abolished CAP1/Prss8
expression in the embryo when it was maintained in placenta
(Fig. 4B). The results presented in the paper thus clearly show that
CAP1 is required for prenatal development, although not within
the embryo itself. Pups lacking CAP1 only in the embryo (but not
in the placenta) were even born according to a Mendelian
distribution (Fig. 5). This clearly shows that the lack of CAP1/
Prss8 during embryonic development is without any consequence
for the embryo. Nevertheless, those pups were born with an
hyperkeratosis as seen in newborns lacking CAP1/Prss8 expres-
sion in the epidermis [29] (Fig. 5), thus causing death shortly after
birth. None of these pups reached the weaning age (Fig. 5), and
the phenotype thus recapitulates the features of an epidermal-
specific CAP/Prss8 knockout.
In conclusion, our study shows that constitutive knockout of
CAP1/Prss8 leads to embryonic lethality due to placental failure.
In addition, CAP1/Prss8 expression within the embryo seems not
required for its development. CAP1/Prss8 is detected in primate
[37] and in human placenta in villi at the level of the trophoblasts
and placental cell lines [38]. Our data strongly suggest that
balanced placental expression of human CAP1/PRSS8 might be
relevant in the context of placental maturation.
Materials and Methods
Animals
Experimental procedures and animal maintenance followed
federal guidelines and were approved by local cantonal authorities.
CAP1/Prss8 constitutive knockouts were obtained by the breeding
of heterozygous males and females (CAP1/Prss8D/+). These mice
and their genotyping have been described previously [28,29].
Sox2::Cre mice were kindly provided by Elizabeth Robertson
(University of Oxford, UK). This Sox2::CreTg/+ transgene is
inducing recombination in the epiblast [39,40]. Male CAP1/
Prss8D/+ Sox2::Cretg/+ mice were crossed with CAP1/Prss8lox/lox
females in order to obtain embryo-specific knockouts. Cre
genotyping was performed using PCR (primer1, sense, 59-
CCTGGAAAATGCTTCTGTCCG-39, primer 2, antisense, 59-
CAGGGTGTTATAAGCAATCCC-39). All experiments were
performed coded.
Ethics Statement
All animal work was conducted according to Swiss national
guidelines. All mice were kept in the animal facility under UNIL
animal care regulations. They were housed in individual cages at
2361uC with a 12-h light/dark cycle. All animals were supplied
with food and water ad libitum. This study has been reviewed and
approved (authorization no. 1793.1 to EH) by the ‘‘Service de la
consommation et des affaires ve´te´rinaires’’ of the canton of Vaud,
Switzerland.
Extraction of Embryonic and Perinatal Tissues
Breedings were started in the evenings, and females were
checked for vaginal plugs the next morning, with the morning of
plug defined as E0.5. Embryos were recovered at indicated time
points, and embryos and placentas were dissected individually.
Visceral yolk sacs of each embryo were washed in PBS and
processed for genomic DNA extraction and genotyping. Placenta
and embryos were separated, rinsed in PBS, and either fixed in
formalin over night prior to paraffin embedding, or snap-frozen in
liquid nitrogen prior to protein/RNA extractions. Embryos were
counted as alive when a beating heart was observed (from E10.5
onwards). Additionally, from E12.5 onwards, viability of embryos
was assessed by color and visible pulsative vascularization.
Histology
2–3 mm sections were obtained from paraffin blocks and stained
with H&E. Labyrinth thickness was measured using ImageJ.
Table 1. Primers used for quantitative PCR.
TaqMan Prss8 For CCCATCTGCCTCCCTGC
Rev CCATCCCGTGACAGTACAGTGA
Probe CCAATGCCTCCTTTCCCAACGGC
Gcm-1 For TACAGCTCGGACGACAGGAA
Rev AGCAGCTGGGCCATGGGCAA
Probe CCCCAGGCATGACTTCTTGA
ß-Actin For AGGTCATCACTATTGGCAACGA
Rev CACTTCATGATGGAATTGAATGTAGTT
Probe TGCCACAGGATTCCATACCCAAGAAGG
SybR green pRB For CTGGCCTGTGCTCTTGAAGT
Rev TGAGGCTGCTTGTGTCTCTG
Eomes For ACATAAAAATTCAGAATCTCTAAAAAG
Rev GATTCATATCTTGGAGATATTCTGT
PAR2 For ACCTGGCAAGAAGGCTAAGA
Rev GACTGAAGCTCTACCAGGGC
ß-Actin For TGGAATCCTGTGGCATCCATGAAA
Rev TAAAACGCAGCTCAGTAACAGTCCG
doi:10.1371/journal.pone.0055796.t001
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Quantitative RT-PCR
Embryonic and placental total RNAs were extracted with
Qiazol (Qiagen, Basel, Switzerland). The reverse transcription
reaction was performed with 1 mg of RNA mixed in a final volume
of 20 ml with oligo dT(20) primer (5 mM), dNTP (500 mM), buffer
(50 mM TrisHCl pH 8.3, 75 mM KCl, 3 mM MgCl2; 5 mM
DTT), and 40 U of SuperscriptII (Invitrogen, Basel, Switzerland).
The reaction was incubated at 42uC for 1 h and finally stopped by
denaturing the enzyme for 10 min at 70uC. The cDNA was
diluted five times before measurements. Quantitative real-time
PCRs were performed by TaqMan PCR using the Applied
Biosystems 7500 (primers and probes used detailed in table 1). The
universal TaqMan mix (2x) and SybR green mix (2x) were
purchased and used according to the manufacturer’s instructions
(Applied Biosystems, Foster City, CA). The quantifications were
calculated by measuring the DDCt normalized to ß-actin level. All
measurements were done in duplicate. All values are expressed in
relative expression (in % of the actin expression level). Primers
were used as listed in Table 1.
Calculation and Statistics
All data are expressed as means6 SEM. Individual groups were
compared by using the t test for unpaired comparisons. The
Mendelian distributions were analysed by chi-square tests. A level
of P,0.05 was accepted as statistically significant for all
comparisons. *P,0.05, **P,0.01, ***P,0.001.
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